RxDoctor Payments Data

Jordan Johnson, MD

Retina Specialist · Oklahoma City, OKNPI 1851682470

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations.

$3,675in general payments, 2019–2025

Across 115 payments — averaging $31.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$508
  • Biogen$495
  • AbbVie$339
  • Coherus Oncology, Inc.$330
  • Alimera Sciences, Inc.$315
  • Apellis Pharmaceuticals, Inc.$304
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,675100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,366,013
Medicare patients
1,096
Services billed
52,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate107$3,006
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$656
MoxifloxacinMoxifloxacin Hcl30$528
Latanoprost87$427
Brimonidine Tartrate28$267
Timolol Maleate27$199
ErythromycinErythromycin Base14$169

Paid to pharmacies, not to this prescriber.

Other retina specialist in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →